| Followers | 34 |
| Posts | 1282 |
| Boards Moderated | 0 |
| Alias Born | 05/10/2010 |
Thursday, October 02, 2025 6:56:03 PM
I agree 100 percent with you,the problem was that the 1st PR was not done correctly and the update was what should have been put out first.The 1st PR is why it tanked.Crucial details was not on the 1st PR like the partner has commercial infrastructure to compete with existing ketamine competitors in the USA market and other markets around the world that they are working on with other companies and other details.
Bullish
Recent PHRRF News
- PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness • Newsfile • 04/21/2026 12:00:00 PM
- PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides • Newsfile • 04/20/2026 12:00:00 PM
- PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery • Newsfile • 04/16/2026 12:00:00 PM
- PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology • Newsfile • 04/13/2026 12:00:00 PM
- PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches • Newsfile • 03/26/2026 12:00:00 PM
- PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market • Newsfile • 03/03/2026 01:00:00 PM
- PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success • Newsfile • 02/02/2026 02:27:00 PM
- PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs • Newsfile • 01/14/2026 01:00:00 PM
- PharmaTher CEO Publishes Letter to Shareholders • Newsfile • 01/02/2026 01:00:00 PM
- PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise • Newsfile • 12/02/2025 02:53:00 PM
- PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program • Newsfile • 11/17/2025 01:00:00 PM
- PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale • Newsfile • 10/17/2025 12:26:00 PM
- PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease • Newsfile • 10/16/2025 12:00:00 PM
- PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings • Newsfile • 10/15/2025 12:00:00 PM
- PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease • Newsfile • 10/08/2025 12:00:00 PM
- PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy • GlobeNewswire Inc. • 10/02/2025 12:00:00 PM
- PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate over US$25 Million in Milestone and Profit-Sharing Payments • Newsfile • 10/01/2025 12:00:00 PM
- PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments • GlobeNewswire Inc. • 10/01/2025 12:00:00 PM
- Psychedelic Pharma Stock Surges on FDA Breakthrough • AllPennyStocks.com • 08/11/2025 07:30:00 PM
